NCT00500292View on ClinicalTrials.gov

A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

November 30, 2016

Conditions
ColorectalCancer
Interventions
DRUG

Vandetanib

once daily oral tablet two dose strengths

DRUG

FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid

intravenous infusion

Trial Locations (15)

Unknown

Research Site, Lille

Research Site, Toulouse

Research Site, Budapest

Research Site, Debrecen

Research Site, Szeged

Research Site, Bratislava

Research Site, Poprad

Research Site, Trnava

Research Site, Žilina

Research Site, Seoul

Research Site, Hospitalet deLlobregat

Research Site, Oviedo

Research Site, Santander

Research Site, Taipei

Research Site, Taoyuan District

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00500292 - A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer | Biotech Hunter | Biotech Hunter